CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: CSF levels of established Alzheimer's disease (AD) biomarkers remain stable despite disease progression, and non-amyloid non-tau biomarkers have the potential of informing disease stage and progression. We previously identified complement 3 (C3) to be decreased in AD dementia, but this change was not found by others in earlier AD stages. We hypothesized that levels of C3 and associated factor H (FH) can potentially distinguish between mild cognitive impairment (MCI) and dementia stages of AD, but we also found their levels to be influenced by age and disease status. RESULTS: We developed a biochemical/bioinformatics pipeline to optimize the handling of complex interactions between variables in validating biochemical markers of disease. We used data from the Alzheimer's Disease Neuro-imaging Initiative (ADNI, n = 230) to build parallel machine learning models, and objectively tested the models in a test cohort (n = 73) of MCI and mild AD patients independently recruited from Emory University. Whereas models incorporating age, gender, APOE ε4 status, and CSF amyloid and tau levels failed to reliably distinguish between MCI and mild AD in ADNI, introduction of CSF C3 and FH levels reproducibly improved the distinction between the two AD stages in ADNI (p < 0.05) and the Emory cohort (p = 0.014). Within each AD stage, the final model also distinguished between fast vs. slower decliners (p < 0.001 for MCI, p = 0.007 for mild AD), with lower C3 and FH levels associated with more advanced disease and faster progression. CONCLUSIONS: We propose that CSF C3 and FH alterations may reflect stage-associated biomarker changes in AD, and can complement clinician diagnosis in diagnosing and staging AD using the publically available ADNI database as reference.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“Genome wide association studies have shown polymorphisms in complement receptor 1 (CR1) to be associated with genetic risks to AD [12].”
BackgroundGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationProminent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162350199 · Cited by 446 · cited 1×
“Earlier data showed that C3 deactivation enhanced AD pathology in transgenic mice [32], and more recent data showed that acetylcholine enhances C3 activation in astrocytes in vitro [33].”
BackgroundDiagnostic neuroimaging across diseases
Klöppel, S., Abdulkadir, A., Jack, C. R., Koutsouleris, N., Mourão-Miranda, J., & Vemuri, P. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.002 · Cited by 279
Fluctuations of CSF amyloid-β levels: Implications for a diagnostic and therapeutic biomarker
Bateman, R. J., Wen, G., Morris, J. C., & Holtzman, D. M. (2007) · Neurology · doi:10.1212/01.wnl.0000256043.50901.e3 · Cited by 260
Neuron Enriched Nuclear Proteome Isolated from Human Brain
Dammer, E. B., Duong, D. M., Diner, I., Gearing, M., Feng, Y., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2013) · Journal of Proteome Research · doi:10.1021/pr400246t · Cited by 70 · cited 1×
“CSF C3 and FH levels were also analyzed in 16 randomly chosen Emory MCI and mild AD subjects in two independent runs of (LC/MS-MS) as described previously [24].”
MethodSelf-citation
Cited by
TLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease
Yang, J., Wise, L., & Fukuchi, K.-I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00724 · Cited by 387
Terminal complement pathway activation drives synaptic loss in Alzheimer’s disease models
Carpanini, S. M., Torvell, M., Bevan, R. J., Byrne, R. A. J., Daskoulidou, N., Saito, T., Saido, T. C., Taylor, P. R., Hughes, T. R., Zelek, W. M., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01404-w · Cited by 95
Blanco, K., Salcidua, S., Orellana, P., Sauma-Pérez, T., León, T., Steinmetz, L. C. L., Ibañez, A., Duran-Aniotz, C., & de la Cruz, R. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01304-8 · Cited by 73
Metadata
- Authors
- Initiative, F. T. A. D. N.-I., Hu, W. T., Watts, K. D., Tailor, P., Nguyen, T. P., Howell, J. C., Lee, R. C., Seyfried, N. T., Gearing, M., Hales, C. M., Levey, A. I., Lah, J. J., & Lee, E. K.
- Venue
- Acta Neuropathologica Communications
- Published
- 2016-02-17
- Volume
- 4
- Issue
- 1
- Pages
- 14-14
- ISSN
- 2051-5960 (ISSN-L)
- OpenAlex
- W2280940680
- Cited by
- 45
- References
- 7
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s40478-016-0277-8
- The paper
- Initiative, F. T. A. D. N.-I., Hu, W. T., Watts, K. D., Tailor, P., Nguyen, T. P., Howell, J. C., Lee, R. C., Seyfried, N. T., Gearing, M., Hales, C. M., Levey, A. I., Lah, J. J., & Lee, E. K. (2016). CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease. Acta Neuropathologica Communications. https://doi.org/10.1186/s40478-016-0277-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.